Interim long-term data from the ongoing ralinepag phase 3 ADVANCE EXTENSION open-label study to be presented at a mini symposium An annual update of the preliminary baseline data from the TETON ...

United Therapeutics (UTHR) announced that ten posters and presentations across its commercial and development portfolio will be presented at ...

We hold diverse political beliefs, but we are united as researchers in wanting ... San Francisco David Andrew Agard, PhD Professor University of California, San Francisco Ian Agol, PhD Professor ...

Today, we are looking at therapeutics stocks, starting with United Therapeutics (NASDAQ:UTHR). Over the next few years, therapeutic companies, which develop a wide variety of treatments for ...

Presented by Andrew Stine, United Therapeutics. Poster Session 1. Cardiology, Sunday, April 27, 6:00 – 7:00 p.m. ET: 447 – Clinical Correlations with Cardiac Power Output-to-Mass and Left ...

A month has gone by since the last earnings report for United Therapeutics (UTHR). Shares have lost about 4.8% in that time frame, underperforming the S&P 500. Will the recent negative trend ...

United Therapeutics Co. has a fifty-two week low of $230.39 and a fifty-two week high of $417.82. The company’s 50-day moving average is $323.22 and its 200 day moving average is $351.09.

It is worth considering United Therapeutics (UTHR), which belongs to the Zacks Medical - Drugs industry. This drugmaker has an established record of topping earnings estimates, especially when ...